Compare GSL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | HROW |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2008 | 2008 |
| Metric | GSL | HROW |
|---|---|---|
| Price | $44.48 | $36.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $44.00 | ★ $69.86 |
| AVG Volume (30 Days) | 363.5K | ★ 532.4K |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | N/A | $50.77 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.28 | $28.54 |
| 52 Week High | $45.45 | $54.98 |
| Indicator | GSL | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 39.88 |
| Support Level | $37.00 | $32.74 |
| Resistance Level | $45.07 | $42.40 |
| Average True Range (ATR) | 0.98 | 1.85 |
| MACD | 0.05 | -0.34 |
| Stochastic Oscillator | 75.63 | 14.71 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.